GlobeNewswire

New Private Aviation Report Reveals the Preferences of the Business Elite and Wealthy Fliers

Dela

Wealth-X and VistaJet Present The Jet Traveler Report: The Global Perspective on Who Flies Privately and How

 

LONDON, March 28, 2018 (GLOBE NEWSWIRE) -- Today Wealth-X, the global leader in wealth information and insight, and VistaJet, the first and only global private aviation company, have released the first customer-centric analysis on the private aviation industry. The Jet Traveler Report: The Global Perspective on Who Flies Privately and How provides unique insight into the profiles of private fliers around the globe, how they fly and what is most important to them.

To download the complete report, please visit: vistajet.com/TheJetTravelerReport

Private aviation is growing. But the global UHNW population and the world's fleet are not rising at the same rate, highlighting that not everyone who flies privately on a regular basis owns a plane. Most of the growth comes from an increase in other flying solutions, including membership programs, fractional ownership and on-demand chartering, allowing individuals access to a fleet of private jets at their convenience.

Wealth-X leveraged its international database of dossiers on UHNW individuals (with a net worth of $30 million or greater) to profile passengers using different methods to fly. The voice of the flier has been brought to life in the report through in-depth interviews with experts, to discover how they travel and why.

To compare the different types of fliers, The Jet Traveler Report classifies the UHNW travelers into three groups:

  • Owners: Owning an aircraft, or part thereof;
  • Members: Members of a private flying program;
  • The wider UHNW audience: Those who use a variety of methods to fly, including private chartering and commercial airlines.

"By identifying who these individuals are and understanding how and why they fly, we gain a clear understanding of the choices facing them and the typologies that exist in the market," said Winston Chesterfield, Director, Wealth-X Custom Research.  "It doesn't always come down to a simple matter of personal wealth - in fact, many owners are also members of private flying programs. It is common for the ultra-wealthy to use more than one way of flying, depending on their needs."

As business leaders and the UHNW population are presented with a vast array of options, VistaJet and Wealth-X have identified five key factors that influence how they choose to fly:

  1. Maximizing time
  2. Control
  3. Perceptions of safety
  4. Mitigating risk
  5. Perceived value

Each flying solution has subsequently been objectively assessed against these requirements, to create an index that provides a streamlined approach to compare flying options from the customer's perspective.

Key findings of the report include:

  • The average wealth of Owners and Members is not dissimilar, at $1.5 billion and $1.16 billion respectively - as some value a higher level of flexibility with access to an entire fleet rather than purchasing a single aircraft;
  • A widespread move away from full or fractional ownership - as aircraft depreciation is expected to remain high for most aircraft models, the value is placed more on flying requirements rather than assets acquisition;
  • Increasing demand for longer trips and larger cabins - 85% of new business jet expenditure in the next five years anticipated to be for these sizes of aircraft;
  • A rise of a younger generation of customers, in all regions - their new approach to how they access services will continue to push innovation within the industry.

"At VistaJet, we place our customers at the core of everything we do. When a Member joins our Program, we begin building a preference profile, which we continue to enrich on every flight. It might sound obvious, but the infrastructure required to deliver the level of service that our customers expect on every flight, across 187 countries, 1,600 airports on 24 hours' notice, is incredibly sophisticated," explains Ian Moore, Chief Commercial Officer at VistaJet. "The notion of service has also evolved - it may be about the entertainment on board when traveling with children or it might be about solutions to ensure the utmost privacy during business meetings. Each flight is different, and customers require maximum flexibility whilst experiencing the highest level of service."

The Jet Traveler Report answers the question of who flies privately and how to identify the key typologies of private flyers, including those who look for complete control, those who want to be seamlessly connected anytime, and the occasional flier. The report also includes a look at the most important macro trends that will shape the private jet industry - the future of business aviation is looking buoyant, but not all will share equally in its growth.

As a result of 14 years of investment and development, VistaJet is one of the most technologically integrated companies in business aviation. In addition to its flagship Program membership, VistaJet's new digital solution, Direct, offers customers a fully integrated end-to-end service via its app and website. Following an investment from Rhône Capital last year, VistaJet has become one of Europe's top five - and Malta's first - Unicorn, with its equity valued in excess of $2.5 billion. The company is well placed to capture even more market share by offering global coverage and consistent unparalleled service.

Information : 
Jennifer Farquhar | VistaJet | T: +44 203 617 3077 | jennifer.farquhar@vistajet.com         
Michael Phillips | Wealth-X | T : +1 646 861 7296 | press@wealthx.com

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/8deddf9c-4a12-4d93-8e2e-22f889fee5a6

http://www.globenewswire.com/NewsRoom/AttachmentNg/a424abdc-df90-4bb8-bbf7-de7ad728ff7c




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum